Pharmaceuticals

A high-level Dubai summit unites tech, pharma, and policy to combat the GCC's escalating IBD crisis, heralding a new era of AI-driven care and IL-23 therapies.

A Boston biotech is making waves with a novel drug and a rapid-screening platform, a one-two punch designed to eliminate drug-resistant cancer stem cells.

As its lead therapy for NCFB enters clinical trials, Revagenix promotes a seasoned drug developer to steer its patient-centric strategy in the chronic disease market.

As Qlosi refill rates hit 49%, Orasis shuns telehealth trends, investing in programs that put eye care professionals back at the center of care.

Verrica Pharma's deal with Medomie brings YCANTH®, a novel skin treatment, to Israel, highlighting a strategy that blends global growth with public health.

Lonza licenses its elite ADC tech to Engitix, a biotech targeting the hidden battlefield of the extracellular matrix. A quiet move with loud implications.

A new partnership promises to solve digital health's fragmentation problem, linking therapy access with AI-driven adherence to create a new benchmark for value.

PolyPid inks a transformative partnership with Azurity for its surgical infection drug, D-PLEX100, securing over $320M and a clear path to market.

Jupiter Neurosciences' $100M deal for a novel MDMA drug signals a major strategic shift, betting on a new era of psychedelic medicine in the U.S.

A new Virginia pharmacy isn't just local expansion. It's a look at the high-tech, high-touch future of elder care and a strategic play in a growing market.

For the fourth year, McLaren's KSP earns a rare 'Pioneer' award from URAC, not just for its performance, but for helping shape the future of patient care.

An upcoming FDA meeting on peptide compounding is more than a regulatory footnote. It's a battleground for the future of personalized and preventive care.

At AIDS 2026, ViiV Healthcare unveils data challenging treatment norms, proving long-acting injectable efficacy, and paving the way for quarterly PrEP.

Berlin-based OMEICOS gets a major FDA boost, advancing its novel PMD drug OMT-28 directly to a pivotal Phase 3 trial. A deep dive into the science.

Arcturus Therapeutics heads to the Canaccord Growth Conference to spotlight its advanced mRNA platform, shifting focus from COVID vaccines to rare diseases.

New research reveals how IntraBio's AQNEURSA recalibrates cellular function, a novel mechanism that could revolutionize treatment for a wide range of diseases.

A Rwandan-owned company reports promising results for a long-acting TB drug. It could transform treatment, but it also signals a shift in global health innovation.

A new study validates Actinogen's cortisol-inhibiting drug for depression, creating a strategic tailwind for its primary Alzheimer's program due in November.

Kamada's new plasma supply agreement is more than just revenue; it's a bold validation of its vertical integration strategy in a competitive global market.

With a new CEO famed for a $2.4B exit and a reverse merger in play, Mentari Therapeutics isn't just developing drugs; it's building a powerhouse.